Rhythm Pharmaceuticals: A Hidden Growth Stock Soaring
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 02 2026
0mins
Should l Buy RYTM?
Source: Fool
- Significant Market Potential: Rhythm Pharmaceuticals has a market cap of $6.8 billion, and despite its relatively small size, its stock has outperformed both Alphabet and Nvidia over the past 12 months, indicating strong market performance and investor confidence.
- Notable Sales Growth: The company's sole approved drug, Imcivree, achieved sales of $194 million in 2025, reflecting a year-over-year increase of approximately 50%, highlighting the growing market demand in the rare genetic obesity treatment sector.
- Promising Clinical Trials: Rhythm expects to advance its oral MC4R agonist, bivamelagon, into Phase 3 clinical testing in 2026, alongside another candidate, RM-718, in Phase 1 testing, showcasing the diversity of its pipeline and potential for market expansion.
- FDA Approval Catalyst: The anticipated FDA approval for Imcivree in treating acquired hypothalamic obesity on March 20, 2026, could potentially benefit over 36,000 patients across the U.S., Europe, and Japan, significantly enhancing the company's market outlook and profitability prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RYTM?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RYTM
Wall Street analysts forecast RYTM stock price to rise
15 Analyst Rating
14 Buy
1 Hold
0 Sell
Strong Buy
Current: 93.000
Low
123.00
Averages
140.62
High
167.00
Current: 93.000
Low
123.00
Averages
140.62
High
167.00
About RYTM
Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Rhythm Pharmaceuticals Reports Positive Phase 3 Trial Data for Setmelanotide
- Significant BMI Reduction: Rhythm Pharmaceuticals reported an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks in the TRANSCEND trial, indicating a positive outlook for treating acquired hypothalamic obesity, which may bolster investor confidence.
- Primary Endpoint Achieved: The trial involved 142 patients, with 94 receiving setmelanotide therapy showing a mean BMI reduction of 16.4%, while the placebo group experienced a 2.4% increase, highlighting the drug's efficacy.
- Hunger Score Improvement: Among patients aged 12 and older, the setmelanotide group showed an average weekly reduction of 2.5 points in hunger scores compared to a 1.3-point reduction in the placebo group, demonstrating the drug's potential in appetite control.
- FDA Application Progress: The company has submitted a supplemental New Drug Application for setmelanotide to the FDA, with a decision expected by March 20, which could position it as the first approved treatment for this condition, enhancing market appeal.
See More
Rhythm Pharmaceuticals Reports Positive Phase 3 Results for Obesity Treatment
- Clinical Trial Results: Rhythm Pharmaceuticals' global Phase 3 TRANSCEND trial demonstrated a mean BMI reduction of 16.4% in patients treated with Setmelanotide over 52 weeks, contrasting with a 2.4% increase in the placebo group, indicating significant efficacy.
- Patient Cohort Analysis: Among the 142 participants, including a Japanese cohort, the results highlighted Setmelanotide's superior performance in weight reduction and hunger score improvement, particularly in patients aged 12 and older.
- Regulatory Application Progress: Rhythm has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA, with a PDUFA goal date of March 20, 2026, while also pursuing regulatory reviews in Europe and Japan, with potential approvals expected later this year.
- Market Performance: RYTM's stock has traded between $45.90 and $122.20 over the past year, closing at $92.73, down 5.45%, but showing a slight recovery of 0.08% in after-hours trading, reflecting market interest in the new therapy.
See More
Rhythm Pharmaceuticals Reports Positive Data on Weight Loss Therapy Setmelanotide
- Clinical Trial Results: Rhythm Pharmaceuticals' global Phase 3 TRANSCEND trial data for 142 patients at 52 weeks shows an 18.8% placebo-adjusted difference in BMI reduction, with a mean BMI decrease of 16.4% in 94 patients on setmelanotide compared to a 2.4% increase in the placebo group, indicating significant efficacy.
- Hunger Score Improvement: Among patients aged 12 and older, the setmelanotide group experienced an average weekly reduction of 2.5 points in hunger scores, compared to a 1.3-point reduction in the placebo group, with statistical significance at p=0.0015, highlighting the drug's potential in hunger management.
- Regulatory Progress: Rhythm's supplemental New Drug Application (sNDA) is under review by the FDA with a PDUFA goal date of March 20, 2026, and the final data package is expected to be submitted on March 2, 2026, further advancing market access.
- International Market Expansion: The company plans to submit a marketing authorization application for setmelanotide to Japan's PMDA and anticipates receiving marketing authorization from the European Commission in the second half of 2026, demonstrating its strategic global positioning and market potential.
See More
RYTM Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: RYTM's 52-week low is $45.905 per share, while the high is $122.20, with the last trade at $91.99, indicating significant price volatility and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $91.99 is close to the 52-week low, potentially prompting investors to reassess its future performance, especially as the price is below the 200-day moving average, suggesting short-term downside risks.
- Market Sentiment Impact: The fluctuations in RYTM's stock price may be influenced by overall market sentiment, particularly amid increasing economic uncertainty, leading investors to be more cautious, which could affect trading volume and price trends.
- Investor Focus: As RYTM's stock price approaches the 52-week low, investors may pay close attention to changes in its fundamentals and future earnings expectations to decide whether to buy or sell at the current price level.
See More
Rhythm Pharmaceuticals Reports Strong Q4 Results Exceeding Expectations
- Earnings Beat: Rhythm Pharmaceuticals reported a Q4 loss of $0.73 per share, better than the expected loss of $0.81, indicating improvements in cost control and operational efficiency, which bolstered investor confidence.
- Sales Growth: The company's sales reached $57.253 million, exceeding market expectations of $56.042 million, demonstrating strong global sales growth for IMCIVREE and further solidifying its market position in rare disease treatments.
- Future Growth Strategy: CEO David Meeker stated that the company is focused on long-term growth and is well-capitalized to achieve important commercial and clinical milestones in 2026, particularly in bringing IMCIVREE to patients with acquired HO in the U.S.
- Analyst Rating Upgrades: Analysts from Guggenheim and Citizens raised their price targets for Rhythm Pharmaceuticals from $140 and $167 to $143 and $176, respectively, reflecting optimistic market expectations regarding the company's future growth potential.
See More
Rhythm Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Rhythm Pharmaceuticals reported Q4 2025 IMCIVREE sales of $57.3 million, a 12% sequential increase, with total annual revenue reaching $194.8 million, approximately 50% higher than 2024, indicating robust market performance.
- Clinical Progress on Track: CEO Meeker noted that the Bivamelagon HO study showed 11 out of 14 patients achieving over 10% BMI reduction at 40 weeks, with plans to present 52-week data at a mid-year medical meeting, marking a smooth transition to Phase 3 trials.
- International Market Expansion: IMCIVREE is now available in over 25 countries, including 8 newly added markets, showcasing the company's growth potential globally, particularly among the estimated 5,000 to 8,000 HO patients in Japan.
- Positive Future Outlook: Management anticipates 2026 non-GAAP operating expenses to range from $385 million to $415 million, reflecting ongoing investments in clinical programs and confidence in future growth, while planning to have Bivamelagon Phase 3 trial drug supply ready by year-end 2026.
See More
Rhythm Pharmaceuticals Reports Positive Phase 3 Trial Data for Setmelanotide
- Significant BMI Reduction: Rhythm Pharmaceuticals reported an 18.8% placebo-adjusted difference in BMI reduction at 52 weeks in the TRANSCEND trial, indicating a positive outlook for treating acquired hypothalamic obesity, which may bolster investor confidence.
- Primary Endpoint Achieved: The trial involved 142 patients, with 94 receiving setmelanotide therapy showing a mean BMI reduction of 16.4%, while the placebo group experienced a 2.4% increase, highlighting the drug's efficacy.
- Hunger Score Improvement: Among patients aged 12 and older, the setmelanotide group showed an average weekly reduction of 2.5 points in hunger scores compared to a 1.3-point reduction in the placebo group, demonstrating the drug's potential in appetite control.
- FDA Application Progress: The company has submitted a supplemental New Drug Application for setmelanotide to the FDA, with a decision expected by March 20, which could position it as the first approved treatment for this condition, enhancing market appeal.
See More
Rhythm Pharmaceuticals Reports Positive Phase 3 Results for Obesity Treatment
- Clinical Trial Results: Rhythm Pharmaceuticals' global Phase 3 TRANSCEND trial demonstrated a mean BMI reduction of 16.4% in patients treated with Setmelanotide over 52 weeks, contrasting with a 2.4% increase in the placebo group, indicating significant efficacy.
- Patient Cohort Analysis: Among the 142 participants, including a Japanese cohort, the results highlighted Setmelanotide's superior performance in weight reduction and hunger score improvement, particularly in patients aged 12 and older.
- Regulatory Application Progress: Rhythm has submitted a supplemental New Drug Application (sNDA) to the U.S. FDA, with a PDUFA goal date of March 20, 2026, while also pursuing regulatory reviews in Europe and Japan, with potential approvals expected later this year.
- Market Performance: RYTM's stock has traded between $45.90 and $122.20 over the past year, closing at $92.73, down 5.45%, but showing a slight recovery of 0.08% in after-hours trading, reflecting market interest in the new therapy.
See More
Rhythm Pharmaceuticals Reports Positive Data on Weight Loss Therapy Setmelanotide
- Clinical Trial Results: Rhythm Pharmaceuticals' global Phase 3 TRANSCEND trial data for 142 patients at 52 weeks shows an 18.8% placebo-adjusted difference in BMI reduction, with a mean BMI decrease of 16.4% in 94 patients on setmelanotide compared to a 2.4% increase in the placebo group, indicating significant efficacy.
- Hunger Score Improvement: Among patients aged 12 and older, the setmelanotide group experienced an average weekly reduction of 2.5 points in hunger scores, compared to a 1.3-point reduction in the placebo group, with statistical significance at p=0.0015, highlighting the drug's potential in hunger management.
- Regulatory Progress: Rhythm's supplemental New Drug Application (sNDA) is under review by the FDA with a PDUFA goal date of March 20, 2026, and the final data package is expected to be submitted on March 2, 2026, further advancing market access.
- International Market Expansion: The company plans to submit a marketing authorization application for setmelanotide to Japan's PMDA and anticipates receiving marketing authorization from the European Commission in the second half of 2026, demonstrating its strategic global positioning and market potential.
See More
RYTM Stock 52-Week Highs and Lows Analysis
- Price Fluctuation Analysis: RYTM's 52-week low is $45.905 per share, while the high is $122.20, with the last trade at $91.99, indicating significant price volatility and reflecting market interest and investor sentiment changes.
- Technical Indicator Observation: The current price of $91.99 is close to the 52-week low, potentially prompting investors to reassess its future performance, especially as the price is below the 200-day moving average, suggesting short-term downside risks.
- Market Sentiment Impact: The fluctuations in RYTM's stock price may be influenced by overall market sentiment, particularly amid increasing economic uncertainty, leading investors to be more cautious, which could affect trading volume and price trends.
- Investor Focus: As RYTM's stock price approaches the 52-week low, investors may pay close attention to changes in its fundamentals and future earnings expectations to decide whether to buy or sell at the current price level.
See More
Rhythm Pharmaceuticals Reports Strong Q4 Results Exceeding Expectations
- Earnings Beat: Rhythm Pharmaceuticals reported a Q4 loss of $0.73 per share, better than the expected loss of $0.81, indicating improvements in cost control and operational efficiency, which bolstered investor confidence.
- Sales Growth: The company's sales reached $57.253 million, exceeding market expectations of $56.042 million, demonstrating strong global sales growth for IMCIVREE and further solidifying its market position in rare disease treatments.
- Future Growth Strategy: CEO David Meeker stated that the company is focused on long-term growth and is well-capitalized to achieve important commercial and clinical milestones in 2026, particularly in bringing IMCIVREE to patients with acquired HO in the U.S.
- Analyst Rating Upgrades: Analysts from Guggenheim and Citizens raised their price targets for Rhythm Pharmaceuticals from $140 and $167 to $143 and $176, respectively, reflecting optimistic market expectations regarding the company's future growth potential.
See More
Rhythm Pharmaceuticals Q4 2025 Earnings Call Highlights
- Significant Revenue Growth: Rhythm Pharmaceuticals reported Q4 2025 IMCIVREE sales of $57.3 million, a 12% sequential increase, with total annual revenue reaching $194.8 million, approximately 50% higher than 2024, indicating robust market performance.
- Clinical Progress on Track: CEO Meeker noted that the Bivamelagon HO study showed 11 out of 14 patients achieving over 10% BMI reduction at 40 weeks, with plans to present 52-week data at a mid-year medical meeting, marking a smooth transition to Phase 3 trials.
- International Market Expansion: IMCIVREE is now available in over 25 countries, including 8 newly added markets, showcasing the company's growth potential globally, particularly among the estimated 5,000 to 8,000 HO patients in Japan.
- Positive Future Outlook: Management anticipates 2026 non-GAAP operating expenses to range from $385 million to $415 million, reflecting ongoing investments in clinical programs and confidence in future growth, while planning to have Bivamelagon Phase 3 trial drug supply ready by year-end 2026.
See More
